Developments in MMJ Research

Developments in MMJ Research

A brief look at recent developments in MMJ research and law:

The journal Health Affairs published a study (read the abstract here) indicating that states with medical cannabis laws see a decrease in Medicare Part D spending. Medicare Part D is a federal program that subsidizes prescription drug costs and insurance premiums. The study indicates a $165 million reduction in Part D costs, thanks to states which have implemented medical cannabis laws.

A Maine law to help reduce opioid abuse went into effect Friday, July 29. The new regulations affect thousands of Mainers, requiring many of them to step down from their existing doses of opioids, in addition to other requirements on providers and pharmacists.

While the media highlight the potential for these patients to seek relief on the illicit market, the efficacy of cannabis to aid in reducing opioid dependence has been under-reported. For more information on the use of cannabis with opioids, check out these resources:

Prescribing cannabis for harm reduction (2012)

Opioid and cannabinoid synergy in a mouse neuropathic pain model (2016)

Cannabis as substitute for alcohol and other drugs (2009)

Developments in MMJ Research